Zafgen Taps Biogen Exec Priya Singhal as New R&D Chief

On the heels of positive Phase 2 data for its lead product, an experimental type 2 diabetes treatment, Zafgen (NASDAQ: [[ticker:ZFGN]]) has hired Priya Singhal as head of R&D. Singhal was most recently a senior VP at Biogen. Zafgen is trying to bounce back from the 2016 decision to abandon its then-lead drug candidate beloranib, a potential treatment for obesity in patients with a rare disease known as Prader-Willi syndrome.

Author: Alex Lash

I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.